Reference
Takagi Y, et al. Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety. Ophthalmology and Therapy 5: 191-206, No. 2, Dec 2016. Available from: URL: http://doi.org/10.1007/s40123-016-0057-3 - Japan
Rights and permissions
About this article
Cite this article
Tafluprost/timolol. Reactions Weekly 1633, 661 (2017). https://doi.org/10.1007/s40278-017-24928-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-24928-x